Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 15/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14577865 | 0.91 | ACHE (0.59) | ACHEHTR1ADRD2HTR2AHTR2C | |
| SCHEMBL8791519 | 0.87 | ACHE (0.60) | ACHEHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL8790451 | 0.86 | ACHE (0.59) | ACHEHTR1ADRD2HTR2AHTR2C | |
| SCHEMBL5578131 | 0.86 | HDAC1 (0.62) | ACHEHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL8791390 | 0.85 | ALDH1A1 (0.59) | ACHE | |
| SCHEMBL7236538 | 0.85 | ACHE (0.74) | ACHE | |
| Hydrochloric Acid SCHEMBL9201633 | 0.84 | ACHE (0.73) | ACHE | |
| Hydrochloric Acid SCHEMBL8789998 | 0.84 | ACHE (0.58) | ACHE | |
| SCHEMBL8790909 | 0.83 | ACHE (0.56) | ACHE | |
| Hydrochloric Acid SCHEMBL7246562 | 0.83 | ACHE (0.65) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0560235-B1 | Condensed heterocyclic ketone derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-06-04 | — | — | EP | claimed |
| US-5462934-A | Cholinesterase inhibitor; learning enhancement | TAKEDA CHEMICAL INDUSTRIES (JP) | 1995-10-31 | — | — | US | claimed |
| EP-0560235-A1 | Condensed heterocyclic ketone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1993-09-15 | — | — | EP | claimed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| EP-1604653-A1 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20040116457-A1 | Agents for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | ACHE 1/4885HDAC1 291/4885HDAC6 559/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | ACHE 1/4885HDAC1 304/4885HDAC6 399/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | ACHE 1/4885HDAC1 231/4885HDAC6 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.